MICHAEL S. WEISS - 28 May 2025 Form 4 Insider Report for Checkpoint Therapeutics, Inc. (CKPT)

Role
Director
Signature
/s/ James F. Oliviero, Attorney-in-Fact
Issuer symbol
CKPT
Transactions as of
28 May 2025
Transactions value $
$64,500
Form type
4
Filing time
30 May 2025, 11:21:17 UTC
Previous filing
30 Jan 2025
Next filing
07 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
WEISS MICHAEL S Director 95 SAWYER ROAD, SUITE 110, WALTHAM /s/ James F. Oliviero, Attorney-in-Fact 30 May 2025 0001038977

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CKPT COMMON STOCK Award $0 +12,195 +9.77% $0 137,007 28 May 2025 See Note 2 F1, F2
transaction CKPT COMMON STOCK Award $64,500 +50,000 +36.49% $1.29 187,007 29 May 2025 Direct
transaction CKPT COMMON STOCK Disposition pursuant to a tender of shares in a change of control transaction -187,007 -100% 0 30 May 2025 See Note 2 F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

MICHAEL S. WEISS is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board.
F2 The shares were held by Hawkins BioVentures, LLC, of which Mr. Weiss is the sole member.
F3 Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency.